Chinese Japanese Germany


Description Clinical research Precautions References
Empagliflozin structure
Chemical Name:
BI-10773;EMpagliflozin;EMPAGLIFLBZIN;Empagliflozin whatsapp;EMpagliflozin/ BI-10773;Empagliflozin Impurity A;Boehringer Ingelheim(BI-44847);Empagliflozin(BI10773,VA10802);Empagliflozin CAS NO.864070-44-0;High purity CAS 129938-20-1 Dapoxetine hcl CAS NO.864070-44-0
Molecular Formula:
Formula Weight:
MOL File:

Empagliflozin Properties

Boiling point:
Flash point:


Empagliflozin price More Price(4)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 17375 Empagliflozin ≥98% 864070-44-0 5mg $39 2018-11-13 Buy
Cayman Chemical 17375 Empagliflozin ≥98% 864070-44-0 10mg $70 2018-11-13 Buy
Cayman Chemical 17375 Empagliflozin ≥98% 864070-44-0 50mg $176 2018-11-13 Buy
Cayman Chemical 17375 Empagliflozin ≥98% 864070-44-0 100mg $273 2018-11-13 Buy

Empagliflozin Chemical Properties,Uses,Production


Empagliflozin(trade name Jardiance) is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and causes sugar in the blood to be excreted by the kidneys and eliminated in urine. On August 1, 2014, the Food and Drug Administration (FDA) officially approved the drug for the treatment of type 2 diabetes, to improve and control blood glucose of adults. Empagliflozin is the third SGLT-2 inhibiting drugs approved by FDA. Another two SGLT-2 inhibitor drugs, canagliflozin and dapagliflozin, belonging to Johnson Pharmaceuticals, AstraZeneca and Bristol-Myers Squibb respectively, are approved by FDA in November 2013 and January 2014 respectively. The new drug Empagliflozin’s application to FDA can be described as twists and turns. In March 2014, due to a large particle contamination incident at the empagliflozin production plant in Boehringer, the application of new drug submitted by the Boehringer-Eli Lilly Alliance was rejected by FDA. In June 2014, after reviewing the summary and material submitted by Boehring in March, confirming that the quality management and compliance system of the Boehring drug production facility was acceptable, FDA withdrew the previously issued warning letter. The Boehringer-Eli Lilly Alliance also filed an application with the FDA on June 17th.

Clinical research

FDA approval of empagliflozin(Jardiance) was based on the results of seven clinical trials conducted in nearly 4,500 patients with type 2 diabetes mellitus. Compared to the placebo group, all patients taking empagliflozin(Jardiance) had a significantly lower HbA1c level. The most common adverse reactions are urinary tract infections and female reproductive system infections.
On March 21, 2014, European Medicines Agency (EMA) Commission on Human Medicines recommended the approval of the sodium glucose co-transporter-2 (SGLT2) inhibitor (empagliflozin) for the treatment of adult type 2 diabetes mellitus.
On May 23, 2014, European Medicines Agency (EMA) approved for empagliflozin’s listing in Europe.
On June 16, 2014, the Boehringer-Erya Diabetes Federation released the latest data of empagliflozin Phase II clinical trials at the 74th American Diabetes Association Science Conference (ADA2014). In a two-year study, empagliflozin or glimepiride was used in the treatment of adult patients with type 2 diabetes based on metformin. The results showed that empagliflozin(Jardiance) reduced HbA1c more significantly compared with glimepiride, while the effect of weight and blood pressure treatment are equivalent with glimepiride. Another 52-week study was conducted in patients with type 2 diabetes who were still unable to adequately control blood glucose levels with high doses of insulin (with or without metformin). The results showed that compared with placebo, Jardiance significantly reduced blood glucose levels and weight, and reduced the dose of insulin, with Jardiance or placebo on a daily basis with multiple injections of insulin. In both studies, the safety of empagliflozin was consistent with previous studies.
FDA-related reports write that the drug should not be used in the following types of patients: type 1 diabetes, elevated blood or urine ketones (diabetic ketoacidosis), severe kidney damage, end-stage renal disease or dialysis patients. The most common side effects are urinary tract infections and female genital infections.
Empagliflozin can cause dehydration and lead to decreased blood pressure, resulting in patients with dizziness or fainting and decreased renal function. The risk of older patients, especially those with impaired renal function and diuretics, appears to be greater.
FDA requires Boehring and Eli Lilly to conduct four post-marketing studies: complete ongoing cardiovascular outcome trials, pediatric pharmacokinetics and pharmacodynamics trials, pediatric safety and efficacy trials, toxicity test for the drug (especially effect for renal function, bone and growth and development)


Do NOT use empagliflozin if:
  • you are allergic to any ingredient in empagliflozin
  • you have type 1 diabetes
  • you have high blood or urine ketone levels (diabetic ketoacidosis)
  • you have severe kidney problems or are on dialysis



Empagliflozin is a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.


ChEBI: A C-glycosyl compound consisting of a beta-glucosyl residue having a (4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl group at the anomeric centre. A sodium-glucose co-transporter 2 inhibitor u ed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Empagliflozin Preparation Products And Raw materials

Raw materials

Preparation Products

Empagliflozin Suppliers

Global( 259)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Lianyungang happen teng technology co., LTD
15950718863 CHINA 305 58
TianYuan Pharmaceutical CO.,LTD
+86-755-23284190 13684996853
+86-755-23284190 CHINA 308 58
Shandonghaohong biotechnology Co.,ltd.
0635-6175299 13961496334
0635-6175299 CHINA 44 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 22043 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 20786 55
Hangzhou FandaChem Co.,Ltd.
0086 158 5814 5714 (Mobile; WhatsApp; Telegram)
+86-571-56059825 CHINA 2444 55
020-81716319 CHINA 2548 55
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-34979012 CHINA 663 60
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 CHINA 16534 60
Anqing Chico Pharmaceutical Co., Ltd.
15380796838 CHINA 209 58

View Lastest Price from Empagliflozin manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2019-04-17 Empagliflozin
US $0.00 / KG 1KG 99% 10 mt Hebei Guanlang Biotechnology Co., Ltd.
2018-08-20 Empagliflozin
US $1.00 / KG 1G 98% 100KG career henan chemical co
2018-08-06 Empagliflozin
US $123.10 / G 10G 99% 10KG career henan chemical co

864070-44-0(Empagliflozin)Related Search:

  • EMpagliflozin
  • BI-10773
  • (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol
  • EMpagliflozin/ BI-10773
  • (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol
  • (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxyMethyl)-tetrahydro-2H-pyran-3,4,5-triol
  • D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]M ethyl]phenyl]-, (1S)-
  • (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol Empagliflozin BI 10773
  • Empagliflozin Impurity A
  • (1S)-1,5-Anhydro-1-C-{4-chloro-3-[(4-{[(3S)-oxolan-3-yl]oxy}phenyl)methyl]phenyl}-D-glucitol
  • Boehringer Ingelheim(BI-44847)
  • -
  • API-
  • Empagliflozin whatsapp
  • High purity CAS 129938-20-1 Dapoxetine hcl CAS NO.864070-44-0
  • Empagliflozin CAS NO.864070-44-0
  • Empagliflozin(BI10773,VA10802)
  • Empagliflozin
  • 864070-44-0
  • C23H27ClO7
  • API
  • Inhibitors
Copyright 2017 © ChemicalBook. All rights reserved